In Vietnam, the first three cases of Allo-BMT were successfully performed in 1995 at the Blood Transfusion and Hematology Hospital (BT-H) of Ho Chi Minh City. Donors were HLA fully matched siblings (HLA-A, HLA-B and HLA-DRB1). The patients were a 26-year-old man with CML in chronic phase (CP), a 12-year-old woman with b-thalassemia/Hb E and a 9-year-old girl with b-thalassemia/Hb E. All patients were engrafted with the median time to recover ANC40.5 Â 10 9
/l, and platelet count 420 Â 10 9 /l was 16 and 38 days. At 12 years after transplantation, all three patients are alive and well. Today, Vietnam has five SCT centers; in the north, there are three centers: 108 Military Hospital, Pediatric Institute and Blood transfusion and Hematology Institute; in the middle of Vietnam is Hue Hospital and in the south, the BT-H Hospital of Ho Chi Minh City. Until now, 65 patients have had SCT in Vietnam; among them, 52 patients had SCT at the BT-H Hospital, Ho Chi Minh City. Because of no connection of data between different SCT centers, we present here only the results performed at the BT-H Hospital, Ho Chi Minh City. With Allo-SCT we performed 19 cases with 3 procedures: BMT (4 cases), PBSC (6 cases) and cord blood transplantation (9 cases); patients were diagnosed with AML (n ¼ 7), ALL (n ¼ 1), CML (n ¼ 5) and b-thalassemia (n ¼ 6). Following transplantation, 7 patients (36.84%) relapsed, 12 (63.16%) remained alive and overall survival times: 6.81 ± 1.35 years, disease-free survival times: 6.69 ± 1.4 years (range 0.5-12 years). With Auto-SCT: since November 1996, we have performed 33 cases of autologous PBSC transplantation consisting of without cryopreservation (24 cases) and with cryopreservation (9 cases); patients were diagnosed with AML in CR1 (n ¼ 21), ALL in CR1 (n ¼ 6), CML in CP (n ¼ 5) and non-Hodgkin's lymphoma in CR1 (n ¼ 1). The median age of the patients was 35 years (range 18-46). The median time to recover ANC 40.5 Â 10 9 /l and platelet count 420 Â 10 9 /l was 14 days (range 9-25 days) and 35 days (range 9-120 days). Following transplantation, 18 patients (54.50%) relapsed, 15 (45.45%) remained alive and overall survival times: 5.74 ± 0.82 years and disease-free survival times: 5.48 ± 0.92 years. There was no statistically significant difference of overall survival and disease-free survival between Allo-SCT and Auto-SCT procedures (P40.05). These preliminary data suggest that HSCTs have been used as one of the standard treatments for hematological diseases and malignancies in Vietnam and that cord blood is an alternative source of hematopoietic stem cells for allogeneic transplantation in children. 44.9±13.6 days (n ¼ 9 cases) Platelets 420 000/ml 6 5 ± 7.8 days (n ¼ 4 cases) 43.5 ± 6.8 days (n ¼ 32 cases) 72 ± 12.8 days (n ¼ 9 cases) In Ho Chi Minh City, from 1995 to 2007, at the BT-H Hospital, we performed two transplantation procedures of allogeneic HSCT and autologous HSCT. The source of stem cell was bone marrow, PBSC and cord blood stem cell. In total, 52 cases were done with hematology malignancies and thalassemia diseases.
The estimated cost of hematopoietic SCT at BT-H Hospital:
Allo-HSCT: 20 000 USD Auto-HSCT: 10 000 USD Until now, medical insurance in Vietnam does not cover HSCT, so patients must bear the full cost.
Obstacles in the performance of transplantation in Vietnam: until now, The National Bone Marrow Registry Organization has not yet been created, so finding a fully matched donor is very difficult, and almost all cases were transplanted from sibling donor or cord blood in pediatric patients. Owing to the economic conditions of the Vietnamese people, the cost of transplantation is still very high and we are aiming to arrange with medical insurance authorities to resolve this problem.
Conclusion
BM and cord blood transplantation, a new and growing field in Vietnam, is a promising approach for the management of hematological malignancies and genetic disorder. These data suggest that cord blood is an alternative source of hematopoietic stem cells for allogeneic transplantation in children. In addition, the rapid expansion and efficient collaboration of cord blood banks in Asia will help to supply safe and efficient cord blood units for transplantation. We are continuing to improve the infrastructure and training personnel. These preliminary results are encouraging us to make every effort in both stem cell and cord blood transplantation (Tables 1-6 ).
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